PA
KALV

Parallel Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Parallel Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.8K Buy
1,876
+589
+46% +$9.49K ﹤0.01% 2154
2025
Q4 		$20.8K Sell
1,287
-136
-10% -$1.8K ﹤0.01% 2270
2025
Q3 		$17.3K Hold
1,423
– – ﹤0.01% 2317
2025
Q2 		$16.1K Buy
1,423
+136
+11% +$1.66K ﹤0.01% 2283
2025
Q1 		$14.9K Buy
1,287
+1,184
+1,150% +$12.1K ﹤0.01% 2280
2024
Q4 		$872 Buy
103
+35
+51% +$362 ﹤0.01% 3135
2024
Q3 		$787 Buy
+68
New +$855 ﹤0.01% 3087
2023
Q1 		– Sell
-382
Closed -$2.85K – 3463
2022
Q4 		$2.58K Buy
382
+363
+1,911% +$1.94K ﹤0.01% 2587
2022
Q3 		$0 Buy
+19
New +$266 ﹤0.01% 3333
2021
Q4 		– Sell
-8
Closed – – 3188
2021
Q3 		$0 Sell
8
-37
-82% -$750 ﹤0.01% 3170
2021
Q2 		$1K Buy
+45
New +$1.18K ﹤0.01% 2756

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parallel Advisors's KALV Position: Q1 2026 in Review

Parallel Advisors increased its KalVista Pharmaceuticals (KALV) stake by 46% in Q1 2026, buying an estimated $9.49K and bringing the position to 1,876 shares worth $37.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Parallel Advisors first reported a position in KALV in Q2 2021 and has held it in 11 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Parallel Advisors held 1,876 shares of KalVista Pharmaceuticals worth $37.8K as of Q1 2026.
  • Parallel Advisors bought 589 KalVista Pharmaceuticals shares in Q1 2026, an estimated $9.49K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2154 holding.
  • Parallel Advisors first reported a position in KalVista Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.